[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605730":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Adelphi Real World","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Axial spondyloarthritis (axSpA)",null,"Patients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor.",[13],"Other: observational study",{"label":15,"type":10,"description":16,"interventionNames":17},"Psoriatic arthritis (PsA)","Patients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","observational study","This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.",[9,15],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"SpA Extend Team","CONTACT","+441625 577 829","arwspaextend@adelphigroup.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Royal National Hospital for Rheumatic Diseases","RECRUITING","Bath","Somerset","BA1 3NG","United Kingdom","UK",{"type":40,"coordinates":41},"Point",[42,43],-2.36172,51.3751,{"lat":43,"lon":42},[46,50],{"name":47,"role":27,"phone":48,"phoneExt":10,"email":49},"Clare Davey","01225821800","clare.davey1@nhs.net",{"name":51,"role":52,"phone":10,"phoneExt":10,"email":10},"Dr William Tillett","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100605730","treatment-effectiveness-in-people-with-axspa-or-psa-starting-treatment-with-bimekizumab-risankizumab-guselkumab-upadacitinib-or-a-tnf-inhibitor-100605730",false,"NCT07166315","Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor","Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor","Inclusion Criteria:\n\n* Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).\n* Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.\n* Participant is aged 18 years or older at enrolment.\n\nExclusion Criteria:\n\n-Participation in a clinical trial at enrolment.","ALL","18 Years",{"count":65,"type":66},700,"ESTIMATED","OBSERVATIONAL","This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.",[70,71],"Axial Spondylarthritis (axSpA)","Psoriatic Arthritis (PsA)","2025-09-09",{"date":74,"type":75},"2025-09-10","ACTUAL",{"date":77,"type":75},"2025-07-07",{"date":79,"type":66},"2027-03",{"name":5,"class":6},1]